ARCHIVES

Also in this 8-page issue: NCI advisors approve $15-million set-aside for laboratory testing on “reduced harm” tobacco products.

This article is from The Cancer Letter archive.

Vol. 30 No. 28 | July 9, 2004

Download PDF Visit The Full Archive

Related Articles

Two Phase III Afatinib Trials Demonstrate Prolonged Survival

May 30, 2014

Avon, four companies Fund NABCO Patient Information Services

January 28, 1994

In Brief: House Hearings On NIH Budget Begin Feb. 1; Army Program Is Peer Reviewing Proposals

January 28, 1994

FDA Oncology Division Invites Advocates To Play Early Role In Cancer Drug Review.

March 23, 2001

Hawking Hearings Turn Up Difference Between Management, Staff At FDA

November 20, 1981

ACS Lists Challenges For Global Tobacco Control

January 22, 2010